Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 1
1993 3
1994 2
1997 1
1999 1
2004 1
2006 2
2007 1
2008 1
2009 2
2013 2
2014 2
2016 2
2018 3
2019 1
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Lymphoma-associated skin cancer: incidence, natural history, and clinical management.
Brewer JD, Habermann TM, Shanafelt TD. Brewer JD, et al. Int J Dermatol. 2014 Mar;53(3):267-74. doi: 10.1111/ijd.12208. Epub 2013 Dec 10. Int J Dermatol. 2014. PMID: 24320558 Review.
The two most common situations involving immunosuppression-associated skin cancer are solid organ transplantation and non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL). Patients with lymphoma are more likely to have development of a sec …
The two most common situations involving immunosuppression-associated skin cancer are solid organ transplantation and non-Hodgkin lymphoma ( …
Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.
Bonamichi-Santos R, Castells M. Bonamichi-Santos R, et al. Clin Rev Allergy Immunol. 2018 Jun;54(3):375-385. doi: 10.1007/s12016-016-8556-5. Clin Rev Allergy Immunol. 2018. PMID: 27277133 Review.
Monoclonal antibody targets include CD20, HER-2, EGFR, IL-6 receptor, TNF-alpha, CD30, VEGF-A, IgE, and more, and examples of immune-mediated and inflammatory diseases that respond to monoclonal antibodies include rheumatoid arthritis, Crohn's disease, ulcerative colitis, juvenil …
Monoclonal antibody targets include CD20, HER-2, EGFR, IL-6 receptor, TNF-alpha, CD30, VEGF-A, IgE, and more, and examples of immune-mediate …
Optimal management of skin cancer in immunosuppressed patients.
Brin L, Zubair AS, Brewer JD. Brin L, et al. Am J Clin Dermatol. 2014 Aug;15(4):339-56. doi: 10.1007/s40257-014-0085-5. Am J Clin Dermatol. 2014. PMID: 25015705 Review.
The prevalence of skin cancer is increased amongst immunosuppressed patients such as those with lymphoproliferative disorders including non-Hodgkin lymphoma and chronic lymphocytic leukemia or those with iatrogenic immunosuppression following organ transplant …
The prevalence of skin cancer is increased amongst immunosuppressed patients such as those with lymphoproliferative disorders including non- …
Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K, Dearden CE. Boyd K, et al. Expert Rev Anticancer Ther. 2008 Apr;8(4):525-33. doi: 10.1586/14737140.8.4.525. Expert Rev Anticancer Ther. 2008. PMID: 18402519 Review.
The antibody target is CD52, an antigen expressed on normal lymphocytes as well as many T- and B-cell neoplasms. It therefore has a potential broad application across a spectrum of B- and T-cell malignancies as well as use as an immunosuppressant drug in, for exampl …
The antibody target is CD52, an antigen expressed on normal lymphocytes as well as many T- and B-cell neoplasms. It therefore …
Immunotoxins in the treatment of hematologic malignancies.
Kreitman RJ, Pastan I. Kreitman RJ, et al. Curr Drug Targets. 2006 Oct;7(10):1301-11. doi: 10.2174/138945006778559139. Curr Drug Targets. 2006. PMID: 17073592 Review.
Plant toxins, particularly ricin, are useful for chemically conjugating to monoclonal antibodies, and have shown clinical activity in several types of lymphoma and leukemia. Their dose is generally limited by vascular leak syndrome. ...The only approved drug containing a p …
Plant toxins, particularly ricin, are useful for chemically conjugating to monoclonal antibodies, and have shown clinical activity in severa …
Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies.
Higgins LS, Go RS, Dingli D, Kumar SK, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lust JA, Kapoor P, Leung N, Lin Y, Kourelis TV, Gertz MA, Kyle RA, Gonsalves WI. Higgins LS, et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):447-52. doi: 10.1016/j.clml.2016.04.009. Epub 2016 May 5. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27238425
INTRODUCTION: Necrobiotic xanthogranuloma (NXG) is a rare chronic granulomatous disorder of the skin associated with a monoclonal gammopathy. ...RESULTS: Most patients had a plasma cell dyscrasia consisting of monoclonal gammopathy of undetermined significance in 28 patien …
INTRODUCTION: Necrobiotic xanthogranuloma (NXG) is a rare chronic granulomatous disorder of the skin associated with a monoclonal gam …
Cladribine for the treatment of hematologic malignancies.
Baltz JK, Montello MJ. Baltz JK, et al. Clin Pharm. 1993 Nov;12(11):805-13; quiz 860-2. Clin Pharm. 1993. PMID: 7903917 Review.
Of the conditions that have been treated with cladribine, hairy cell leukemia (HCL) has shown the most dramatic response. Overall response rates in clinical studies have ranged from 80% to 100%, with a large majority of these being complete remissions; median durations of …
Of the conditions that have been treated with cladribine, hairy cell leukemia (HCL) has shown the most dramatic response. Overall res …
Association of multiple primary melanomas with malignancy risk: A population-based analysis of entries from the Surveillance, Epidemiology, and End Results program database during 1973-2014.
Cai ED, Swetter SM, Sarin KY. Cai ED, et al. J Am Acad Dermatol. 2023 May;88(5):e211-e219. doi: 10.1016/j.jaad.2018.09.027. Epub 2018 Oct 2. J Am Acad Dermatol. 2023. PMID: 30287320 Free PMC article.
The most common malignancies among MPM patients included breast, prostate, thyroid, soft tissue, brain, kidney, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Risk for subsequent cutaneous melanoma increased with observed:expected ratios of 8. …
The most common malignancies among MPM patients included breast, prostate, thyroid, soft tissue, brain, kidney, non-Hodgkin lymphoma, and …
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
Adkins JC, Peters DH, Markham A. Adkins JC, et al. Drugs. 1997 Jun;53(6):1005-37. doi: 10.2165/00003495-199753060-00007. Drugs. 1997. PMID: 9179529 Review.
Fludarabine is an antineoplastic agent which has been studied in patients with a variety of lymphoproliferative malignancies. Clinical evidence from comparative studies in chronic lymphocytic leukaemia (CLL) suggests that fludarabine is at least as effective …
Fludarabine is an antineoplastic agent which has been studied in patients with a variety of lymphoproliferative malignancies. Clinical evide …
Differential survival of systemic B-cell lymphomas initially diagnosed in the skin: a population-based study of 883 patients.
Goyal N, Rubin N, Goyal A. Goyal N, et al. Arch Dermatol Res. 2023 Mar;315(2):259-263. doi: 10.1007/s00403-021-02293-0. Epub 2021 Nov 15. Arch Dermatol Res. 2023. PMID: 34779893
This study seeks to quantify the incidence of initial skin presentation in patients with systemic B-cell lymphomas (BCL) via examination of data in the Surveillance, Epidemiology, and End Results (SEER)-18 database; cases of primary cutaneous B-cell …
This study seeks to quantify the incidence of initial skin presentation in patients with systemic B-cell lymphomas (BCL) via e …
28 results